Showing 1 - 9 results of 9 for search 'Guy Young', query time: 0.03s Refine Results
  1. 1
    Nonfactor Therapies for Hemophilia

    Nonfactor Therapies for Hemophilia by Guy Young

    Published 2023-06-01
    Get full text
    Article
  2. 2
    Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays

    Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays by Hande Kizilocak, Clara Lana Yukhtman, Elizabeth Marquez-Casas, Jeanie Lee, Jennifer Donkin, Guy Young

    Published 2019-06-01
    Get full text
    Article
  3. 3
    Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients

    Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients by Anthony K. Chan, Jayanthi Alamelu, Chris Barnes, Ampaiwan Chuansumrit, May‐Lill Garly, Rikke Medom Meldgaard, Guy Young

    Published 2020-10-01
    Get full text
    Article
  4. 4
    S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX

    S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-... by Gili Kenet, Beatrice Nolan, Bulent Zulfikar, Bulent Antmen, Guy Young, Jiarui Chi, Marion Afonso, Viridiana Cano, Christian Sussebach, Shauna Andersson, Kaan Kavakli

    Published 2023-08-01
    Get full text
    Article
  5. 5
    The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease

    The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease by Cornelia Heleen vanOmmen, Manuela Albisetti, Anthony K. Chan, Jeremie Estepp, Julie Jaffray, Gili Kenet, Guy Young, Jay Dave, Michael A. Grosso, Anil Duggal

    Published 2020-07-01
    Get full text
    Article
  6. 6
    Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

    Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study by Dagmar Kubitza, Stefan Willmann, Michael Becka, Kirstin Thelen, Guy Young, Leonardo R. Brandão, Paul Monagle, Christoph Male, Anthony Chan, Gili Kennet, Ida Martinelli, Paola Saracco, Anthonie W. A. Lensing

    Published 2018-12-01
    Get full text
    Article
  7. 7
    Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital‐Acquired Thrombosis consortium

    Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital‐Acquired Thrombosis consortium by Elizabeth T. Stephens, Anh Thy H. Nguyen, Julie Jaffray, Brian Branchford, Ernest K. Amankwah, Neil A. Goldenberg, E. Vincent S. Faustino, Neil A. Zakai, Amy Stillings, Emily Krava, Guy Young, John H. Fargo

    Published 2022-10-01
    Get full text
    Article
  8. 8
    S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

    S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSI... by Gili Kenet, Beatrice Nolan, Bulent Zulfikar, Bulent Antmen, Peter Kampmann, Tadashi Matsushita, Chur-Woo You, Kateryna Vilchevska, Catherine N. Bag, Azizan Sharif, Flora Peyvandi, Guy Young, Claude Negrier, Christian Sussebach, Fadi Shammas, Shauna Andersson, Baisong Mei, Kaan Kavakli

    Published 2023-08-01
    Get full text
    Article
  9. 9
    Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

    Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study by Anthonie W. A. Lensing, Christoph Male, Guy Young, Dagmar Kubitza, Gili Kenet, M. Patricia Massicotte, Anthony Chan, Angelo C. Molinari, Ulrike Nowak-Goettl, Ákos F. Pap, Ivet Adalbo, William T. Smith, Amy Mason, Kirstin Thelen, Scott D. Berkowitz, Mark Crowther, Stephan Schmidt, Victoria Price, Martin H. Prins, Paul Monagle

    Published 2018-12-01
    Get full text
    Article

Search Tools: